Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Ein cyf / Our ref: 597/16/FOI You asked us: Please complete the tables provided. * * ** ** 1. TNM staging for metastatic Urothelial Cancer = Any T, any N, M1 TNM staging for locally advanced Urothelial Cancer = Any T, N2-3, M0 or T4b, any N, M0 TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0 TNM staging for Stage IV NSCLC = Any T, any N, M1 Within your Health Board how many patients are currently [within the past 6 months] being treated with a chemotherapy agent [not including surgery/radiotherapy only]; 2. All Non-Small Cell Lung Cancer patients Patients with Non-Small Cell Lung Cancer (NSCLC) Stage IIIB**/IV** (Stage 3b/4) Of the NSCLC patients, please state the number of patients currently [within the past 6 months] being treated with the following therapies; 1&2 The Health Board does not hold all of the data in a format that would enable us to fully respond to your request to the level of detail required. Many of the drugs have multiple uses and our systems do not record if these drugs were for patients with NSCLC Stage IIIB**/IV** (Stage 3b/4). Treatment Afatinib (Giotrif) Ceritinib (Zykadia) Crizotinib (Xalkori) Erlotinib (Tarceva) Gefitinib (Iressa) Nitendaninb + docetaxel Nivolumab (Opdivo) Pemetrexed (Alimta) mono or in combination with carboplatin / cisplatin Number of Patients 7 0 2 10 1 7 0 16 patients on Pemetrexed Cyfeiriad Gohebiaeth ar gyfer y Cadeirydd a'r Prif Weithredwr / Correspondence address for Chairman and Chief Executive: Swyddfa'r Gweithredwyr / Executives’ Office, Ysbyty Gwynedd, Penrhosgarnedd Bangor, Gwynedd LL57 2PW Gwefan: www.pbc.cymru.nhs.uk / Web: www.bcu.wales.nhs.uk Pembrolizumab (Keytruda) Gemcitabine mono or in combination with carboplatin / cisplatin Paclitaxel mono or in combination with carboplatin / cisplatin Doxetaxel mono or in combination with carboplatin / cisplatin Vinorelbine [or other Vinka alkaloid] mono or in combination with carboplatin / Cisplatin 3. 0 Not able to obtain data as this drug is used in multiple disease sites Not able to obtain data as this drug is used in multiple disease sites Not able to obtain data as this drug is used in multiple disease sites Not able to obtain data as this drug is used in multiple disease sites If your Health Board does not treat these cancers and you refer your patients to another trust, please state which trust? Not applicable. 4. Within your Health Board how many patients are currently [within the past 6 months] diagnosed with Urothelial cancer? All Urothelial cancer (UCC, also transitional cell carcinoma or TCC) patients (TREATED or UNTREATED); Metastatic* or locally advanced* Urothelial cancer (UCC, also transitional cell carcinoma or TCC) patients The Health Board has diagnosed 75 urothelial cancers in the 6 month period July to December 2016. 5. Of these patients (metastatic/locally advanced UCC), please state the number of patients currently [within the past 6 months] being treated with the following therapies; For the following table, we cannot distinguish the number of patients for the specific indication as they are used for multiple disease sites. Treatment Cisplatinum single agent Cisplatinum in combination with another agent Carboplatinum single agent Carboplatinum in combination with another agent Any other chemo regimen without cisplatinum or carboplatinum Number of Patients Not able to obtain data as this drug is used in multiple disease sites Not able to obtain data as this drug is used in multiple disease sites Not able to obtain data as this drug is used in multiple disease sites Not able to obtain data as this drug is used in multiple disease sites Not able to obtain data as this drug is used in multiple disease sites